News

Cushman & Wakefield - Golden Triangle Report - Q1

Cushman & Wakefield has released its latest Life Sciences Lab Report on the UK's Golden Triangle. The Golden Triangle report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London.

Headlines:

Q4 2023 Take-Up Statistics

- Golden Triangle leasing activity totalled 169,000 sq ft in Q1 2024.

- Whilst a step down from the 364,000 leased in Q4 2023, it remained 5% above the five-year quarterly average.

11 installs successfully completed

Novel platform automates and accelerates protein production, enabling scale-up to mg amount in less than 48 hours

List of institutes includes, University College London, University of Cambridge, University of Southampton, University of Manchester, The Flanders Institute for Biotechnology (VIB) in Belgium, and the CRUK Cambridge Institute

May eNews is Here

Read eNews for May, featuring:

✅ Welcome from Tony Jones, CEO, One Nucleus

✅ It's All About the Money

✅ Life Sciences Training Made Easy: Your New Sat Nav Guide!

✅ The Good Housekeeping Guide to Dealmaking

GMP Compliant Cell Culture Medium Streamlines API Manufacture

AMSBIO has launched an enhanced GMP-compliant version of its animal-origin-free, chemically defined StemFit™ iPSC expansion medium.

StemFit™ Basic04 CT is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API).

Life Sciences Training Made Easy: Your New Sat Nav Guide!

By Monalisa Breazu, Learning & Development Administrator, One Nucleus

Abzena Launches EpiScreen® 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates

Cambridge, UK, April 25, 2024, Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics. The next-generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early-phase development.

Biocair moves science forward with new science park tour across the UK

To help address logistical challenges and provide supply chain advice to the life science community, Biocair has launched a roadshow to deliver on-site support at a variety of science parks across the UK.

The event series aims to support the vital role logistics plays in ensuring the safe, efficient transportation of invaluable life science materials. Biocair is facilitating this by meeting with industry representatives and providing a physical presence with this open, flexible approach to customer service.

SYGNATURE DISCOVERY GOES FOR GLOBAL INDUSTRY RECOGNITION WITH CHIEF SCIENTIFIC OFFICER HIRE

World-leading contract research organization Sygnature Discovery has announced a major new hire to its leadership team, with the appointment of Dr David Witty as Chief Scientific Officer (CSO) to ensure its integrated drug discovery capabilities remain at the cutting edge of the industry.

David will be responsible for ensuring Sygnature Discovery remains globally recognised for the quality of its scientific operations and is able to attract the top scientific talent in the industry.

New from Thermo Fisher Scientific for Biotech Life Science - Accelerate Your Path to the Next Milestone

It can be challenging to hit your milestones and goals when macroeconomic conditions continue to evolve and change. More than ever, you need to optimise your spend, scale up efficiently, maximise productivity, whilst reducing your environmental impact.

At Thermo Fisher Scientific, we provide you with trusted life science solutions that can enable you to get the most from your resources and help bridge gaps so you can meet your milestones quickly.

One Nucleus and Riverlabs Collaborative Event: How can the UK become the best place to scale a life science company?

This event brought together life science experts and entrepreneurs to explore what should be done to make the UK a scale-up market of choice. The event included a Keynote by George Freeman, MP and a panel discussion, moderated by Lord O’Shaughnessy. The event helped to raise awareness on what factors influence a companies’ decision on where to locate and what policies, investment and other changes can ensure the UK is as attractive and internationally competitive as possible.

My Account